Back to News
Apr 6, 2026 8:00 AM

Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform

– Series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments,

– Stipple Bio is leveraging its Pointillist Platform to identify tumor-specific cell surface epitopes to enable the development of precision oncology medicines with a high therapeutic index,

– Lead candidate STP-100, a novel Antibody Drug Conjugate (ADC) incorporating tumor specific binders designed to avoid on-target/off-tumor toxicity, expected to enter clinical studies in early 2027,

CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the close of a $100 million heavily oversubscribed Series A financing. The financing was co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments, among others. In conjunction with the financing, Derek DiRocco, PhD and Thilo Schroeder, PhD will join the Stipple Bio Board of Directors which already includes Vineeta Agarwala MD, PhD, Owen Hughes, Jeff Landau and Aaron Ring ...